Payment overview · 2025
General Payments
$8,905.59
209 reported records · 28 companies
Healthcare provider profile · identity verified
Roberto O Salcedo, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HERMITAGE, PA · NPI 1417930959
Verified facts
What the public records show
CMS Open Payments records show Roberto O Salcedo, MD received $8,905.59 in general payments during 2025 across 209 reported records.
GENZYME CORPORATION accounted for 56.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Vumerity.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $4,986.69 | 56.0% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $433.06 | 4.9% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $397.01 | 4.5% | 24 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $303.84 | 3.4% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $275.39 | 3.1% | 16 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $263.67 | 3.0% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $252.28 | 2.8% | 19 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $216.42 | 2.4% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $212.24 | 2.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.95 | 2.2% | 11 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $167.63 | 1.9% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $155.68 | 1.8% | 12 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$135.95 | 1.5% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $122.12 | 1.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $104.67 | 1.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.00 | 1.0% | 5 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $84.01 | 0.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.12 | 0.9% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $75.73 | 0.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $74.73 | 0.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.22 | 0.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.72 | 0.5% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $46.27 | 0.5% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $37.79 | 0.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.80 | 0.4% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $32.31 | 0.4% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.68 | 0.2% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.61 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,470.31 | 2 |
| Food and Beverage | $4,435.28 | 207 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $374.76 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $327.88 | 21 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $300.23 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $253.71 | 15 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $216.42 | 16 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $212.24 | 11 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $200.52 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $191.95 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $186.06 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $178.84 | 8 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $155.68 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $146.34 | 15 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $143.04 | 6 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $136.25 | 6 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $135.95 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $127.42 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $122.12 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $108.69 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $104.68 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $104.67 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $87.00 | 5 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $84.01 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $75.73 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $75.73 | 3 | 2025 |
Source payment records
|
|||||
| RYTARY Normalized: rytary |
Drug | Amneal Pharmaceuticals LLC | $74.73 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $6.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 392 | 73 |
| Levetiracetam | Levetiracetam | 317 | 58 |
| Memantine Hcl | Memantine Hcl | 316 | 50 |
| Sertraline Hcl | Sertraline Hcl | 283 | 50 |
| Donepezil Hcl | Donepezil Hcl | 256 | 58 |
| Topiramate | Topiramate | 215 | 38 |
| Gabapentin | Gabapentin | 196 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 140 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 22 |
| Primidone | Primidone | 134 | 29 |
| Lacosamide | Lacosamide | 127 | 16 |
| Carbamazepine | Carbamazepine | 111 | 22 |
| Lamotrigine | Lamotrigine | 104 | 18 |
| Aimovig Autoinjector | Erenumab-Aooe | 76 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 74 | 11 |
| Baclofen | Baclofen | 71 | 13 |
| Trazodone Hcl | Trazodone Hcl | 71 | 18 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | 13 |
| Prednisone | Prednisone | 50 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | 15 |
| Emgality Pen | Galcanezumab-Gnlm | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 27 | suppressed |
| Depakote | Divalproex Sodium | 27 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 17 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Tecfidera | Dimethyl Fumarate | 13 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Vumerity | Diroximel Fumarate | 12 | suppressed |
| Lamictal | Lamotrigine | 11 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,905.59 · 209 records | GENZYME CORPORATION | AJOVY, AUSTEDO XR, Briviact, DAYBUE, Gamunex-C, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, PONVORY, QULIPTA, REXULTI, RYTARY, Radicava, Rystiggo, TRUDHESA, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA, Zilbrysq | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error